Correlation Between Evogene and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both Evogene and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evogene and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Evogene and Lineage Cell Therapeutics, you can compare the effects of market volatilities on Evogene and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evogene with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evogene and Lineage Cell.

Diversification Opportunities for Evogene and Lineage Cell

0.06

Correlation Coefficient

Evogene  Lineage Cell

Significant diversification

The 3 months correlation between Evogene and Lineage is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Evogene and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and Evogene is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evogene are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of Evogene i.e., Evogene and Lineage Cell go up and down completely randomly.

Pair Corralation between Evogene and Lineage Cell

Assuming the 90 days trading horizon Evogene is expected to under-perform the Lineage Cell. But the stock apears to be less risky and, when comparing its historical volatility, Evogene is 1.5 times less risky than Lineage Cell. The stock trades about -0.14 of its potential returns per unit of risk. The Lineage Cell Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  18,020  in Lineage Cell Therapeutics on December 30, 2024 and sell it today you would lose (230.00) from holding Lineage Cell Therapeutics or give up 1.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Evogene  vs.  Lineage Cell Therapeutics

Evogene

Risk-Adjusted Performance

Very Weak

Over the last 90 days Evogene has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Lineage Cell Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Lineage Cell is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Evogene and Lineage Cell

The main advantage of trading using opposite Evogene and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evogene position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind Evogene and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.